Annette Sauter

2.7k total citations
23 papers, 594 citations indexed

About

Annette Sauter is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Annette Sauter has authored 23 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 4 papers in Neurology. Recurrent topics in Annette Sauter's work include Multiple Sclerosis Research Studies (13 papers), Peripheral Neuropathies and Disorders (4 papers) and Bacterial Genetics and Biotechnology (4 papers). Annette Sauter is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Peripheral Neuropathies and Disorders (4 papers) and Bacterial Genetics and Biotechnology (4 papers). Annette Sauter collaborates with scholars based in Switzerland, United States and Germany. Annette Sauter's co-authors include Volkmar Braun, Susanne Mahren, Harold Koendgen, S. Peter Howard, Ludwig Kappos, Amit Bar‐Or, Stephen L. Hauser, Xavier Montalbán, Douglas L. Arnold and A. Donald and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and The Lancet Neurology.

In The Last Decade

Annette Sauter

23 papers receiving 584 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annette Sauter Switzerland	12	303	150	124	111	103	23	594
Nadine Schuerer Austria	8	209 0.7×	72 0.5×	96 0.8×	40 0.4×	18 0.2×	14	479
Roberta Reniè Italy	9	109 0.4×	74 0.5×	114 0.9×	26 0.2×	23 0.2×	18	306
Laurence Guignard Switzerland	8	171 0.6×	19 0.1×	65 0.5×	130 1.2×	26 0.3×	9	455
Courtney R. Johnson United States	11	36 0.1×	79 0.5×	328 2.6×	27 0.2×	57 0.6×	14	712
Jill C. Rau United States	8	55 0.2×	65 0.4×	66 0.5×	17 0.2×	27 0.3×	14	444
Luping Zhang China	15	67 0.2×	18 0.1×	149 1.2×	113 1.0×	20 0.2×	62	674
Nicola Wagner Germany	16	172 0.6×	20 0.1×	233 1.9×	11 0.1×	47 0.5×	49	916
Joseph Taylor United Kingdom	11	29 0.1×	31 0.2×	69 0.6×	57 0.5×	25 0.2×	25	476
Theresa Baker United States	10	64 0.2×	21 0.1×	121 1.0×	20 0.2×	21 0.2×	20	465
Patricia M. Gordon United Kingdom	16	52 0.2×	25 0.2×	157 1.3×	47 0.4×	17 0.2×	26	666

Countries citing papers authored by Annette Sauter

Since Specialization

Citations

This map shows the geographic impact of Annette Sauter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annette Sauter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annette Sauter more than expected).

Fields of papers citing papers by Annette Sauter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annette Sauter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annette Sauter. The network helps show where Annette Sauter may publish in the future.

Co-authorship network of co-authors of Annette Sauter

This figure shows the co-authorship network connecting the top 25 collaborators of Annette Sauter. A scholar is included among the top collaborators of Annette Sauter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annette Sauter. Annette Sauter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kappos, Ludwig, Anthony Traboulsee, David K.B. Li, et al.. (2023). Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. Journal of Neurology. 271(2). 642–657. 10 indexed citations

Bar‐Or, Amit, Christopher Harp, Corrado Bernasconi, et al.. (2023). Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 93. 104662–104662. 46 indexed citations

Schmierer, Klaus, Jerry S. Wolinsky, Bruno Brochet, et al.. (2022). 031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. Journal of Neurology Neurosurgery & Psychiatry. 93(6). A23.1–A23. 1 indexed citations

Hughes, Richard A., Hans‐Martin Schneble, Erwan Muros‐Le Rouzic, et al.. (2020). COVID-19 in ocrelizumab-treated people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 49. 102725–102725. 54 indexed citations

Bar‐Or, Amit, Christopher Harp, Anne Cross, et al.. (2020). Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420). Neurology. 94(15_supplement). 1 indexed citations

Wolinsky, Jerry S., Douglas L. Arnold, Bruno Brochet, et al.. (2020). Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 19(12). 998–1009. 103 indexed citations

Bar‐Or, Amit, Robert Bermel, Martin S. Weber, et al.. (2020). Serum Ig Levels and Risk of Serious Infections by Baseline Ig Quartile in the Pivotal Phase III Trials and Open-Label Extensions of Ocrelizumab in Multiple Sclerosis (1173). Neurology. 94(15_supplement). 7 indexed citations

Benedict, Ralph H. B., J. de Sèze, Stephen L. Hauser, et al.. (2020). Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290). Neurology. 94(15_supplement). 1 indexed citations

Jia, Xiaoming, Christopher Harp, Anne Cross, et al.. (2020). Blood Neurofilament Light Chain Levels and Association with Brain Volume Change in Patients with Primary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis Before and During Ocrelizumab Treatment (3926). Neurology. 94(15_supplement). 1 indexed citations

10.

Bogman, Katrijn, Jochen Brumm, Carsten Hofmann, et al.. (2019). Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Clinical Pharmacokinetics. 58(9). 1205–1214. 2 indexed citations

11.

Barkhof, Frederik, Ludwig Kappos, Jerry S. Wolinsky, et al.. (2019). Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology. 93(19). e1778–e1786. 39 indexed citations

12.

Wolinsky, J. S., Douglas L. Arnold, Amit Bar‐Or, et al.. (2016). Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial. mediaTUM (Technical University of Munich). 63–64. 4 indexed citations

13.

Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2016). Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001). Neurology. 86(16_supplement). 18 indexed citations

14.

Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. mediaTUM (Technical University of Munich). 36 indexed citations

15.

Montalbán, Xavier, Bernhard Hemmer, Kottil Rammohan, et al.. (2015). Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017). Neurology. 84(14_supplement). 2 indexed citations

16.

Hauser, Stephen L., David Li, Peter A. Calabresi, et al.. (2013). Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004). Neurology. 80(7_supplement). 9 indexed citations

17.

Braun, Volkmar, Susanne Mahren, & Annette Sauter. (2006). Gene Regulation by Transmembrane Signaling. BioMetals. 19(2). 103–113. 57 indexed citations

18.

Braun, Volkmar, Susanne Mahren, & Annette Sauter. (2005). Gene Regulation by Transmembrane Signaling. BioMetals. 18(5). 507–517. 12 indexed citations

19.

Feldman, Howard, Annette Sauter, A. Donald, et al.. (2001). The Disability Assessment for Dementia Scale: A 12-Month Study of Functional Ability in Mild to Moderate Severity Alzheimer Disease. Alzheimer Disease & Associated Disorders. 15(2). 89–95. 94 indexed citations

20.

Sauter, Annette. (2001). Xenotransplantation - eine Studie des TAB. SHILAP Revista de lepidopterología. 10(1). 37–42. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact